Article

Use of Antibiotics and Probiotics Reduces the Risk of Metachronous Gastric Cancer after Endoscopic Resection

Junya Arai 1,*, Ryota Niikura 1,2,*, Yoku Hayakawa 1,*, Takuya Kawahara 3, Tetsuro Honda 4, Kenkei Hasatani 5, Naohiro Yoshida 6, Tsutomu Nishida 7, Tetsuya Sumiyoshi 8, Shu Kiyotoki 9, Takashi Ikeya 10, Masahiro Arai 11, Nobumi Suzuki 1, Yosuke Tsuji 1, Atsuo Yamada 1, Takashi Kawai 2 and Kazuhiko Koike 1

1 Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan; jarai-tky@umin.ac.jp (J.A.); nsuzuki-ham@umin.ac.jp (N.S.); ytsuji-tky@umin.ac.jp (Y.T.); yamada-a@umin.ac.jp (A.Y.); kkoike-tky@umin.ac.jp (K.K.)
2 Department of Gastroenterological Endoscopy, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0223, Japan; t-kawai@tokyo-med.ac.jp
3 Clinical Research Promotion Center, The University of Tokyo Hospital, Tokyo 113-8655, Japan; tkawahara-tky@umin.ac.jp
4 Department of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki-shi, Nagasaki 850-8555, Japan; tetsupeacevo@yahoo.co.jp
5 Department of Gastroenterology, Fukui Prefectural Hospital, Fukui-shi, Fukui 910-0846, Japan; k-hasatani-nr@pref.fukui.lg.jp
6 Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa-shi, Ishikawa 920-8530, Japan; ynaohiro@ipch.jp
7 Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka-shi, Osaka 560-8565, Japan; tnishida@gh.med.osaka-u.ac.jp
8 Department of Gastroenterology, Tonan Hospital, Sapporo-shi, Hokkaido 060-0004, Japan; t-sumiyoshi@tonan.gr.jp
9 Department of Gastroenterology, Shuto General Hospital, Yanai-shi, Yamaguchi 333-0801, Japan; shu2026eb@hi.enjoy.ne.jp
10 Department of Gastroenterology, St. Luke’s International Hospital, Chuo-ku, Tokyo 104-8560, Japan; takaie@luku.ac.jp
11 Department of Gastroenterology, Nerima Hikarigaoka Hospital, Nerima-ku, Tokyo 179-0072, Japan; araima-tky@umin.ac.jp
* Correspondence: niikura-dky@umin.ac.jp (R.N.); yhayakawa-tky@umin.ac.jp (Y.H.); Tel.: +81-3-3342-6111 (R.N.);+81-3-3815-5411 (Y.H.)

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Simple Summary: Helicobacter pylori is the most important cause of gastric cancer, and its eradication reduces the incidence of gastric cancer after endoscopic resection. However, incidence of metachronous gastric cancer is still high. More studies are needed to identify other chemopreventive drugs that may reduce the incidence of this disease. In this study, we focused on the alteration of the intragastric microbiome and examined the association between the use of antibiotics and probiotic drugs and risk of metachronous gastric cancer. Our findings suggest that the gut microbiome is associated with metachronous gastric cancer development.

Abstract: Metachronous gastric cancer often occurs after endoscopic resection. Appropriate management, including chemoprevention, is required after the procedure. This study was performed to evaluate the association between medication use and the incidence of metachronous gastric cancer after endoscopic resection. This multicenter retrospective cohort study was conducted with data from nine hospital databases on patients who underwent endoscopic resection for gastric cancer between 2014 and 2019. The primary outcome was the incidence of metachronous gastric cancer. We evaluated the associations of metachronous gastric cancer occurrence with medication use and clinical factors. Hazard ratios were adjusted by age and Charlson comorbidity index scores, with and without consideration of sex, smoking status, and receipt of Helicobacter pylori eradication therapy during the study period. During a mean follow-up period of 2.55 years, 10.39% (140/1347) of all patients developed metachronous gastric cancer. The use of antibiotics other than those used for H. pylori eradication was associated with a lower incidence of metachronous gastric cancer than non-use (adjusted hazard ratio (aHR) 0.56, 95% confidence interval (CI) 0.38–0.85, p = 0.006).
Probiotic drug use was also associated with a lower incidence of metachronous gastric cancer compared with non-use (aHR 0.29, 95% CI 0.091–0.91, p = 0.034). In conclusion, the use of antibiotics and probiotic drugs was associated with a decreased risk of metachronous gastric cancer. These findings suggest that the gut microbiome is associated with metachronous gastric cancer development.

**Keywords:** metachronous gastric cancer; endoscopic resection; antibiotics; probiotics; gut microbiome

### 1. Introduction

*Helicobacter pylori* is the most important cause of gastric cancer [1], and its eradication reduces the incidence of gastric cancer after endoscopic resection [2]. However, long-term observational studies have shown a high incidence of metachronous gastric cancer, estimated at 2–3% per year, even after endoscopic resection and *H. pylori* eradication [3,4]. Although a randomized study conducted in Korea showed that *H. pylori* eradication reduced the risk of metachronous gastric cancer by approximately 50% [5], more studies are needed to identify other chemopreventive drugs that may reduce the incidence of this disease.

Several potentially chemopreventive drugs for gastric cancer have been identified. Statin use has been associated with a 10% reduced risk of gastric cancer [6], and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with a 6% reduction in gastric cancer incidence [7]. Recently, alteration of the intragastric microbiome in gastric cancer tissue has been studied [8]. Dysbiosis involving certain non-*H. pylori* bacteria may be associated with the gastric cancer risk [8]. Bacterial overgrowth may promote gastric carcinogenesis, even after *H. pylori* eradication [9]. Thus, we hypothesized that antibiotics and probiotic drugs might affect dysbiosis and reduce the risk of metachronous gastric cancer.

To address these issues, we performed a multicenter retrospective cohort study of patients who underwent endoscopic resection for gastric cancer and evaluated associations of the use of antibiotics, probiotic drugs, and other medications with the development of metachronous gastric cancer after endoscopic resection.

### 2. Materials and Methods

#### 2.1. Study Design, Setting, and Participants

We performed this retrospective cohort study using combined diagnostic procedure databases from nine hospitals. The study period was April 2014–March 2019. The combined databases provided records for all inpatients at Tonan Hospital and for all inpatients and outpatients at the University of Tokyo Hospital, Shuto General Hospital, Fukui Prefectural Hospital, Nerima Hikarigaoka Hospital, St. Luke’s International Hospital, Toyonaka Municipal Hospital, Ishikawa Prefectural Central Hospital, and the Nagasaki Minato Medical Center. They contained data on diagnosis, comorbidities, and adverse events, recorded using the International Classification of Diseases, 10th revision (ICD-10), as well as on drugs and procedures, coded using the original Japanese system. We used the procedure codes for endoscopic resection, including endoscopic mucosal resection and endoscopic submucosal dissection (K6531–K6534), and the ICD-10 codes for gastric cancer (C160–166, C168, and C169), to extract data for all patients who underwent endoscopic resection for gastric cancer between April 2014 and March 2019. We excluded patients who underwent second endoscopic resections or additional surgical resections for gastric cancer <1 year after the index endoscopic resection. The follow-up period extended from the date of the first endoscopic resection to the final visit. The end of the follow-up period was March 2019, and loss to follow-up was defined using the date of the final visit. We also excluded the patients whose follow-up period was less than 1 year. This study was approved by the institutional review boards of the University of Tokyo Hospital (no. 2019161NI).
2.2. Outcomes and Variables

The primary outcome was the development of metachronous gastric cancer, as defined by ICD-10 codes (C160–C166, C168, and C169) and procedure codes for endoscopic and surgical resection >1 year after the index endoscopic resection (K6531–K6534, K654-2, K654-31, K654-32, K6551, K6552, K655-21, K655-22, K655-41, K655-42, K655-51, K655-52, K656, K656-2, K6571, K6572, K657-21, and K657-22).

We evaluated the following clinical factors: age, sex, smoking status, *H. pylori* eradication drug use, comorbidities, and medication use. Drug codes were used to assess *H. pylori* eradication, which was defined as the prescription of a 7-day course of clarithromycin- or metronidazole-based triple therapy for *H. pylori* infection between April 2014 and March 2019 (Table S1). Age was dichotomized as >70 and ≤70 years. The following comorbidities (based on ICD-10 codes) were included: atrial fibrillation, acquired immunodeficiency syndrome, arterial thrombosis, carotid disease, cerebrovascular disease, chronic heart failure, chronic kidney disease (≤ stage 5), dementia, diabetes mellitus with or without complications, deep vein thrombosis, hemiplegia, dyslipidemia, ischemic heart disease, liver disorder (mild/severe), malignancy with or without metastasis, pulmonary embolism, peripheral vascular disease, pulmonary disease, rheumatic disease, transient ischemic attack, peptic ulcer disease, unstable angina, and valvular disease. Charlson comorbidity index scores were calculated using these data [10]. Details of the ICD-10 codes are shown in Table S1.

We assessed the use of antibiotics, probiotics, NSAIDs (including cyclooxygenase-2 (COX2) inhibitors), aspirin, metformin, statins with other lipid-lowering agents (e.g., fibrates), and proton pump inhibitors (PPI). The use of medications other than antibiotics was defined as a prescription for >60 days. Antibiotics were categorized into groups consisting of two or three major oral medications, such as aminoglycosides, carbapenems, penems, glycopeptides, cephems, tetracyclines, oxazolidinones, quinolones, lincomycin, chloramphenicol, metronidazole, penicillins, fosfomycin, macrolides, and sulfamethoxazole-trimethoprim combinations. Antibiotics used for *H. pylori* eradication therapy were not counted in antibiotic use. Antibiotics in the β-lactam group included penicillin, cephems, carbapenems, and penems. Antibiotics for anaerobic bacteria included lincomycin, metronidazole, carbapenem, and tetracyclines or combinations of β-lactamase inhibitors. Antibiotics for carcinogenic bacteria, such as Fusobacterium spp., Citrobacter spp., and Clostridium spp., included amoxicillin, fosfomycin, metronidazole, tetracycline, and lincomycin [11–15]. Probiotics included the combination of lactic acid bacteria, butyrate-producing bacteria, bifidobacteria, and saccharifying bacteria. Loxoprofen, sulindac, diclofenac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, oxaprozin, naproxen, mefenamic acid, flufenamate aluminum, acemetacin, proglumetacin maleate, molecule, pranoprofen, tiaprofenic acid, zaltoprofen, tiaramide hydrochloride, etodolac, meloxicam, nabumetone, zaltoprofen, lornoxicam, and piroxicam, including COX2 inhibitors (celecoxib), were defined as NSAIDs. Statins included pitavastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, and rosuvastatin. Fibrates included fenofibrate, bezafibrate, clinofibrate, and clofibrate. PPI included omeprazole, lansoprazole, rabeprazole, and esomeprazole. Details of the codes for these medications are shown in Table S2.

2.3. Statistical Analysis

The primary endpoint, metachronous gastric cancer development, was censored on the date of the final visit. The Kaplan–Meier method was used to calculate the cumulative probability of metachronous gastric cancer development at 5 years. Univariate and multivariate Cox models were used to estimate hazard ratios and 95% confidence intervals (CIs). The multivariate Cox proportional hazards models were adjusted for age and Charlson comorbidity index scores, with and without consideration of sex and smoking status, as appropriate. *p* values < 0.05 were considered to be significant. All statistical analyses were performed using the SAS software (ver. 9.4; SAS Institute, Cary, NC, USA).
3. Results

3.1. Patient Characteristics

A total of 2832 patients underwent endoscopic resection for gastric cancer during the study period. After the exclusion of 1485 patients who underwent additional endoscopic or surgical resection within 1 year and whose follow-up period was less than one year, data from 1347 patients were included in the analysis (Figure 1). The mean age of these 1347 patients was 72.54 years, and 75.87% (n = 1021) were male. Overall, 32.00% of the patients used antibiotics, 5.64% used probiotics, 7.20% used aspirin, 9.58% used NSAIDs, 1.41% used COX2 inhibitors, 10.02% used statins, 0.89% used fibrates, 1.04% used other lipid-lowering agents, 3.27% of patients used metformin, and 43.36% of patients used PPI. The baseline characteristics of the cohort are shown in Table 1. Antibiotics were principally used for infections, including respiratory tract infection (3.48%), urinary tract infection (3.02%), skin infection (0.70%), enteritis (0.70%), and biliary tract infection (0.93%).

![Figure 1. Flow of patient selection.](image)

3.2. Incidence of Metachronous Gastric Cancer after Endoscopic Resection and Associated Factors

Factors associated with metachronous gastric cancer, as determined by Cox modeling, are shown in Table 2 and Figure 2. In our patient sample, antibiotic use was associated with a lower incidence of metachronous gastric cancer compared with non-use (adjusted hazard ratio (aHR) 0.56, 95% CI 0.38–0.85, \( p = 0.006 \)). The use of β-lactam antibiotics (aHR 0.61, 95% CI 0.39–0.96, \( p = 0.031 \)), and amoxicillin, fosfomycin, metronidazole, tetracycline, or lincomycin (aHR 0.59, 95% CI 0.36–0.97, \( p = 0.038 \)) was also associated with a decreased risk of metachronous gastric cancer. Probiotic use was associated with a lower incidence of metachronous gastric cancer compared with non-use (aHR 0.29, 95% CI 0.091–0.91, \( p = 0.034 \)). Moreover, the use of statins was associated significantly with a lower incidence of metachronous gastric cancer (aHR 0.52, 95% CI 0.27–0.99, \( p = 0.047 \)).
Conversely, PPI use was associated with a higher risk of metachronous gastric cancer (aHR 1.49, 95% CI 1.05–2.11, \(p = 0.024\)). Clinical factors associated with a higher incidence of metachronous gastric cancer were age >70 years (aHR 1.57, 95% CI 1.09–2.28, \(p = 0.017\)) and peptic ulcer disease (aHR 2.95, 95% CI 2.05–4.24, \(p < 0.001\); Figure S1). No interaction between antibiotics, probiotic drugs, or other medications was observed (Figure S2).

Table 1. Baseline characteristics of patients after endoscopic resection.

| Characteristic                                      | Number of Patients (%) or Mean ± SD |
|----------------------------------------------------|-------------------------------------|
| Sex (male)                                         | 1022 (75.87)                        |
| Age (>70 years)                                    | 845 (62.73)                         |
| Years of follow-up                                 | 2.56 ± 1.04                         |
| Smoking                                            | 685 (50.85)                         |
| H. pylori eradication drug use during the study period | 339 (25.17)                        |
| Charlson comorbidity index                         | 1.52 ± 1.87                         |
| Medications                                        |                                    |
| Antibiotics                                        | 431 (32.00)                         |
| Aminoglycoside                                     | 21 (1.56)                           |
| Carbapenem                                         | 0 (0)                               |
| Cepham (first generation)                          | 20 (1.48)                           |
| Cepham (second generation)                         | 0 (0)                               |
| Cepham (third generation)                          | 118 (8.76)                          |
| Fosfomycin                                         | 2 (0.15)                            |
| Glycopeptide                                       | 0 (0.00)                            |
| Chloramphenicol                                    | 0 (0)                               |
| Macrolide                                          | 159 (11.80)                         |
| Metronidazole                                      | 61 (4.53)                           |
| Oxazolidinone                                      | 0 (0)                               |
| Penicillin                                         | 200 (14.85)                         |
| Penem                                              | 4 (0.30)                            |
| Lincomycin                                         | 3 (0.22)                            |
| ST combination                                     | 18 (1.34)                           |
| Tetracycline                                       | 8 (0.59)                            |
| Quinolone                                          | 135 (11.51)                         |
| \(\beta\)-lactam §                                 | 301 (22.35)                         |
| Antibiotics for anaerobic bacteria ¶               | 108 (8.02)                          |
| Antibiotics for carcinogenic bacteria ‡            | 234 (17.37)                         |
| Probiotics                                         | 76 (5.64)                           |
| Aspirin                                            | 97 (7.20)                           |
| NSAIDs                                             | 129 (9.58)                          |
| COX2I (celecoxib only)                             | 19 (1.41)                           |
| Statin                                             | 135 (10.02)                         |
| Fibrate                                            | 12 (0.89)                           |
| Other lipid-lowering agent                         | 14 (1.04)                           |
| Metformin                                          | 44 (3.27)                           |
| Proton pump inhibitor                              | 584 (43.36)                         |

Abbreviations: SD, standard deviation; ST, sulfamethoxazole-trimethoprim; NSAID, nonsteroidal anti-inflammatory drug; COX2I, cyclooxygenase-2 inhibitor. § Antibiotics in the \(\beta\)-lactam class included penicillins, cephems, carbapenems, and penems. ¶ Antibiotics for anaerobic bacteria included lincomycin, metronidazole, carbapenem, and tetracycline antibiotics and combinations with \(\beta\)-lactamase inhibitors. ‡ Antibiotics for carcinogenic bacteria included amoxicillin, fosfomycin, metronidazole, tetracycline, and lincomycin.

During the mean follow-up period of 2.55 years, 140 (10.39%) patients developed metachronous gastric cancer (of them, 29 patients eradicated \(H. \text{pylori}\) during the study period). The cumulative incidence of gastric cancer was 10.62% at 3 years and 12.48% at 5 years in patients using antibiotics, and 14.11% at 3 years and 35.68% at 5 years in patients not using antibiotics (Figure 3). Antibiotic use was associated significantly with a decreased incidence of gastric cancer (log-rank test, \(p = 0.026\)). This result was similar to another Kaplan–Meier analysis in the propensity score matched cohort, calculated by age, sex, CCI,
and several infections (Figure S3). The cumulative incidence of gastric cancer was 6.06% at 3 and 5 years in patients using probiotics, and 12.95% at 3 years and 27.88% at 5 years in patients not using probiotics (Figure 3). Probiotic use was associated significantly with a decreased incidence of gastric cancer (log-rank test, \( p = 0.045 \)).

### Table 2. Medications associated with metachronous gastric cancer after endoscopic resection.

| Factor                  | Metachronous Gastric Cancer (\( n = 140 \)) | No Metachronous Gastric Cancer (\( n = 1207 \)) | Crude HR (95% CI) | Adjusted HR † (95% CI) | \( p \)       |
|-------------------------|---------------------------------------------|-----------------------------------------------|-------------------|------------------------|------------|
| No antibiotic Antibiotics | 105 (11.46)                                 | 811 (88.54)                                  | 1                 | 1                      |            |
| No probiotic Probiotics | 35 (8.12)                                   | 396 (91.88)                                  | 0.66 (0.45–0.97)  | 0.56 (0.38–0.85)       | 0.006 *    |
| No aspirin Aspirin      | 137 (10.78)                                 | 1134 (89.22)                                 | 0.33 (0.11–1.03)  | 0.29 (0.091–0.91)      | 0.034 *    |
| No NSAID NSAIDs         | 12 (12.37)                                  | 1122 (89.76)                                 | 1                 | 1                      |            |
| No COX2I COX2I          | 138 (10.39)                                 | 1190 (89.61)                                 | 0.81 (0.20–3.27)  | 0.85 (0.21–3.43)       | 0.814      |
| No statin Statins      | 130 (10.73)                                 | 1082 (89.27)                                 | 1                 | 1                      |            |
| No fibrates Fibrates   | 10 (7.41)                                   | 125 (92.59)                                  | 0.60 (0.31–1.14)  | 0.52 (0.27–0.99)       | 0.047 *    |
| No metformin Metformin  | 135 (10.36)                                 | 1168 (89.64)                                 | 1                 | 1                      |            |
| No PPI PPI              | 59 (7.73)                                   | 704 (92.27)                                  | 1                 | 1                      |            |

Abbreviations: HR, hazard ratio; CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug; COX2I, cyclooxygenase-2 inhibitor; PPI, proton pump inhibitor. † HR adjusted for age >70 years, sex, smoking status, and Charlson comorbidity index. *: \( p \) values < 0.05 were considered to be significant.
Development of metachronous gastric cancer

| Antibiotic Type                  | Hazard Ratio |
|----------------------------------|--------------|
| Aminoglycoside                   | 0.28         |
| Carbenem                         | NA           |
| Cephalosporin 1st generation     | 0.38         |
| Cephalosporin 2nd generation     | NA           |
| Cephalosporin 3rd generation     | 0.72         |
| Fosfomycin                       | NA           |
| Glycopeptide                     | NA           |
| Chloramphenicol                  | NA           |
| Macrolide                        | 0.60         |
| Metronidazole                    | 0.58         |
| Oxazolidine                      | NA           |
| Penicillin                       | 0.65         |
| Penem                            | 4.87         |
| Lincomycin                       | NA           |
| ST combination                   | 0.43         |
| Tetracycline                     | NA           |
| Quinolone                        | 0.92         |
| **β-lactam**                     | 0.61         |
| **Antibiotics for anaerobic bacteria** | 0.63      |
| **Antibiotics for carcinogenic bacteria** | 0.59    |

Hazard ratio

Figure 2. Associations of antibiotic use with metachronous gastric cancer development after endoscopic resection. Abbreviations: CI, confidence interval; aHR, adjusted hazard ratio; ST, sulfamethoxazole-trimethoprim. † HR adjusted for age >70 years and Charlson comorbidity index. § Antibiotics in the β-lactam class included penicillin, cephem, carbapenem, and penem. ¶ Antibiotics for anaerobic bacteria included lincomycin, metronidazole, carbapenem, tetracycline antibiotics, and combinations with β-lactamase inhibitors. ‡ Antibiotics for carcinogenic bacteria included amoxicillin, fosfomycin, metronidazole, tetracycline, and lincomycin. *: p values < 0.05 were considered to be significant.

Figure 3. Cumulative incidence of metachronous gastric cancer in (A) antibiotic users vs. non-users and (B) probiotic users vs. non-users. Survival analysis was performed using the Kaplan–Meier method and log-rank test. *: p values < 0.05 were considered to be significant.
4. Discussion

In this multicenter cohort study, we found that antibiotic and probiotic drug use was associated with a decreased risk of metachronous gastric cancer after endoscopic resection. In addition, statin use reduced the risk of metachronous gastric cancer development by 20%. Other medications did not significantly decrease this risk. These findings suggest that the gut microbiome is associated with metachronous gastric cancer development, and support previous findings of an association between dysbiosis and gastric cancer [8].

In this study, the use of all types of antibiotics was associated with a decreased incidence of metachronous gastric cancer (Figure 2). In particular, β-lactam antibiotic use decreased the risk of metachronous gastric cancer by 21%. Wide-spectrum antibiotics may affect various types of bacteria, consequently improving dysbiosis and decreasing the incidence of metachronous gastric cancer. Interestingly, the use of amoxicillin, fosfomycin, metronidazole, tetracycline, and lincomycin also tended to decrease the risk of metachronous gastric cancer. These antibiotics affect several bacterial strains that are reported to be carcinogenic in the gastrointestinal tract, including Fusobacterium spp., Citrobacter spp., and Clostridium spp. [11–15]. Our results are consistent with previous findings of associations between certain bacteria and gastric cancer. In our study, probiotics use was also associated significantly with a decreased incidence of metachronous gastric cancer (Figure 3B). Probiotics included butyrate-producing bacteria and Bifidobacterium, which have shown anti-carcinogenic effects in vitro and in vivo and may improve dysbiosis [16,17].

In contrast with previous studies [18–20], the associations of statin, aspirin, and COX2 inhibitor use with a decreased risk of metachronous gastric cancer did not reach statistical significance in this study. We suggest two reasons for this discrepancy. First, our study included patients with and without H. pylori infection, whereas previous studies included only patients in whom H. pylori had been eradicated. The difference in the prevalence of H. pylori infection might affect the chemopreventive potential of these drugs. The discrepancy may also be attributable to our examination of a relatively small number of patients over a short follow-up period, which may have limited our ability to detect the chemopreventive effects of these drugs.

Our study had several strengths. First, we evaluated associations of the use of a variety of medications with the incidence of metachronous gastric cancer after endoscopic resection. Second, the study had a multicenter cohort design. Nevertheless, our study had several limitations. First, it was retrospective. Second, our combined diagnostic procedure database lacked data on the success of H. pylori eradication before and during the study period. However, 5.75% of patients in our sample developed metachronous gastric cancer during the study period. In contrast, metachronous gastric cancer had developed in 3.30% of patients in an H. pylori eradication group and 8.82% of patients in a non-eradication group at the 3-year follow-up point in a previous study [2]. The incidence of metachronous gastric cancer in our study was consistent with that in the previous study. Thus, we speculate that the proportion of patients with H. pylori eradication did not differ significantly between our study and previous studies. Third, the follow-up period was relatively short and insufficient to accurately evaluate metachronous gastric cancer events. However, we will expand our database to double the number of hospitals and will perform further studies for another 2 years in the near future. Finally, the data was collected in a single country, Japan, where the incidence of gastric cancer is relatively high. The result of this study might not be applied to other countries where the incidence of gastric cancers is low as metachronous gastric cancer itself is very rare. Further studies in various countries are needed in the future.

5. Conclusions

In conclusion, the use of antibiotics and probiotics was associated with a decreased risk of metachronous gastric cancer. These medications may be candidate agents for the pre-
vention of metachronous gastric cancer after endoscopic resection. These findings suggest that the gut microbiome is associated with metachronous gastric cancer development.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/biology10060455/s1, Figure S1: Hazard ratios for metachronous gastric cancer based on clinical factors after endoscopic resection, Figure S2: Interactions of (A) antibiotics and (B) probiotics with all other medications, Figure S3: Cumulative incidence of metachronous gastric cancer in antibiotic users vs. non-users in propensity score matched cohort, calculated by age, sex, charlson comorbidity index, and several infections, Table S1: ICD-10 codes for comorbidities, Table S2: Drug codes.

**Author Contributions:** J.A., R.N. and Y.H. contributed to the study design. J.A. wrote the initial manuscript draft. J.A., R.N. and T.K. (Takuya Kawahara) analyzed the data. T.H., K.H., N.Y., T.N., T.S., S.K., T.I., M.A., N.S., Y.T., A.Y., T.K. (Takashi Kawai) and K.K. provided guidance regarding the study design and contributed to manuscript editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by KAKENHI Grants-in-Aid for Scientific Research [grant nos. 20K08375 (R. N.) and 17H05081 (Y. H.)]. Y.H. is also supported by JSPS, Inoue Science Research Award, Takeda Science Foundation Visionary Research Grant, Uehara Memorial Foundation, Naito Foundation, Daiwa-Shoken health foundation, The Waksman Foundation of Japan, Koyanagi Foundation, The Research Foundation for Pharmaceutical Sciences, Yakult Bio-Science Foundation, Tokyo Biochemical Research Foundation, The NOVARTIS Foundation (Japan) for the Promotion of Science, SGH foundation, Daichi Sankyo Foundation of Life Science, and AMED (PRIME and P-CREATE). The funding agencies had no role in the design of the study, data collection or analyses, decision to publish, or preparation of the manuscript.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of the institutional review boards of the University of Tokyo [ID: 10329].

**Informed Consent Statement:** Patient consent was waived due to the fact that DPC data is anonymous.

**Data Availability Statement:** All data presented in this study are included within the paper and its supplementary files.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

**References**

1. Correa, P.; Piazuelo, M.B.; Camargo, M.C. The future of gastric cancer prevention. *Gastric Cancer* **2004**, *7*, 9–16. [CrossRef] [PubMed]
2. Fukase, K.; Kato, M.; Kikuchi, S.; Inoue, K.; Uemura, N.; Okamoto, S.; Terao, S.; Amagai, K.; Hayashi, S.; Asaka, M. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. *Lancet* **2008**, *372*, 392–397. [CrossRef]
3. Abe, S.; Oda, I.; Suzuki, H.; Nonaka, S.; Yoshinaga, S.; Nakajima, T.; Sekiguchi, M.; Mori, G.; Taniguchi, H.; Sekine, S.; et al. Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection. *Endoscopy* **2015**, *47*, 1113–1118. [PubMed]
4. Mori, G.; Nakajima, T.; Asada, K.; Shimazu, T.; Yamamichi, N.; Maekita, T.; Yokoi, C.; Fujishiro, M.; Gotoda, T.; Ichinose, M.; et al. Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful Helicobacter pylori eradication: Results of a large-scale, multicenter cohort study in Japan. *Gastric Cancer* **2016**, *19*, 911–918. [CrossRef] [PubMed]
5. Choi, I.J.; Kook, M.-C.; Kim, Y.-J.; Cho, S.-J.; Lee, J.Y.; Kim, C.G.; Park, B.; Nam, B.-H. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. *N. Engl. J. Med.* **2018**, *378*, 1085–1095. [CrossRef] [PubMed]
6. Cheung, K.S.; Chan, E.W.; Wong, A.Y.S.; Chen, L.; Seto, W.K.; Leung, W.K.; Sung, J.J.Y.; Lin, J.T. Effective reduction of gastric cancer risk in patients with eradicated Helicobacter pylori infection: A territory-wide propensity score matched study. *Cancer Epidemiol. Biomarkers Prev.* **2020**, *29*, 493–499. [CrossRef] [PubMed]
7. Wu, C.Y.; Wu, M.S.; Kuo, K.N.; Wang, C.B.; Chen, Y.J.; Lin, J.T. Effective reduction of gastric cancer risk with regular use of non-steroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. *J. Clin. Oncol.* **2010**, *28*, 2952–2957. [CrossRef] [PubMed]
8. Coker, O.O.; Dai, Z.; Nie, Y.; Zhao, G.; Cao, L.; Nakatsu, G.; Wu, W.K.; Wong, S.H.; Chen, Z.; Sung, J.J.Y.; et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. *Gut* **2018**, *67*, 1024–1032. [CrossRef] [PubMed]
9. De Witte, C.; Schulz, C.; Smet, A.; Malfertheiner, P.; Haesebrouck, F. Other Helicobacters and gastric microbiota. Helicobacter 2016, 21 (Suppl. 1), 62–68. [CrossRef]
10. Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic. Dis. 1987, 40, 373–383. [CrossRef]
11. Koido, S.; Ohkusa, T.; Kajiura, T.; Shinozaki, J.; Suzuki, M.; Saito, K.; Takakura, K.; Tsukinaga, S.; Odahara, S.; Yukawa, T.; et al. Long-Term Alteration of Intestinal Microbiota in Patients with Ulcerative Colitis by Antibiotic Combination Therapy. PLoS ONE 2014, 9, e86702. [CrossRef] [PubMed]
12. Ishikawa, D.; Sasaki, T.; Takahashi, M.; Kuwahara-Arai, K.; Haga, K.; Ito, S.; Okahara, K.; Nakajima, A.; Shibuya, T.; Osada, T.; et al. The Microbial Composition of Bacteroidetes Species in Ulcerative Colitis Is Effectively Improved by Combination Therapy with Fecal Microbiota Transplantation and Antibiotics. Inflamm. Bowel Dis. 2018, 24, 2590–2598. [CrossRef] [PubMed]
13. Nadkarni, M.D.; Verchick, J.; O’Neill, J.C. Lemierre syndrome. J. Emerg. Med. 2005, 28, 297–299. [CrossRef] [PubMed]
14. Yamamura, K.; Baba, Y.; Miyake, K.; Nakamura, K.; Shigaki, H.; Mima, K.; Kurashige, J.; Ishimoto, T.; Ivatsuki, M.; Sakamoto, Y.; et al. Fusobacterium nucleatum in gastroenterological cancer: Evaluation of measurement methods using quantitative poly-merase chain reaction and a literature review. Oncol. Lett. 2017, 14, 6373–6378. [CrossRef] [PubMed]
15. Ferreira, R.M.; Pereira-Marques, J.; Pinto-Ribeiro, I.; Costa, J.L.; Carneiro, F.; Machado, J.C.; Figueiredo, C. Gastric microbial com-munity profiling reveals a dysbiotic cancer-associated microbiota. Gut 2018, 67, 226–236. [CrossRef] [PubMed]
16. Hirayama, K.; Rafter, J. The role of probiotic bacteria in cancer prevention. Microbes Infect. 2000, 2, 681–686. [CrossRef]
17. Malaguarnera, G.; Leggio, F.; Vacante, M.; Motta, M.; Giordano, M.; Biondi, A.; Basile, F.; Mastrojeni, S.; Mistretta, A.; Malaguarnera, M.; et al. Probiotics in the gastrointestinal diseases of the elderly. J. Nutr. Health Aging 2012, 16, 402–410. [CrossRef] [PubMed]
18. Chung, H.; Kim, H.J.; Jung, H.C.; Lee, S.K.; Kim, S.G. Statins and metachronous recurrence after endoscopic resection of early gas-tric cancer: A nationwide Korean cohort study. Gastric Cancer 2020, 23, 659–666. [CrossRef] [PubMed]
19. Watari, J.; Tomita, T.; Tozawa, K.; Oshima, T.; Fukui, H.; Miwa, H. Preventing Metachronous Gastric Cancer after the Endoscopic Resection of Gastric Epithelial Neoplasia: Roles of Helicobacter pylori Eradication and Aspirin. Gut Liver 2020, 14, 281–290. [CrossRef] [PubMed]
20. Yanaoka, K.; Oka, M.; Yoshimura, N.; Deguchi, H.; Mukoubayashi, C.; Enomoto, S.; Maekita, T.; Inoue, I.; Ueda, K.; Utsunomiya, H.; et al. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int. J. Cancer 2010, 126, 1467–1473. [PubMed]